For the quarter ending 2025-09-30, KLRS made $13,594K in revenue. -$11,888K in net income. Net profit margin of -87.45%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development (including 0, 32,056, 15 and 32,115 for a related party, respectively) | 9,126 | 8,440 | ||
| General and administrative (including 71, 56, 269 and 153 for a related party, respectively) | 3,615 | 3,816 | ||
| Total operating expenses | 12,741 | 12,256 | ||
| Loss from operations | -12,741 | -12,256 | ||
| Change in fair value of tranche liability (including 331 for a related party for the nine months ended september 30, 2025) | 0 | 0 | ||
| Change in fair value of derivative liabilities (including 0, 549, 1,165 and 860 for a related party, respectively) | 0 | 0 | ||
| Interest expense (including 0, 815, 1,384 and 1,392 for a related party, respectively) | 0 | 0 | ||
| Loss on extinguishment and on issuance of convertible promissory notes (including 0, 0, 169 and 2,134 for a related party, respectively) | 0 | 0 | ||
| Other income, net | 847 | 906 | ||
| Total other income (expense), net | 847 | 906 | ||
| Net loss | -11,894 | -11,350 | ||
| Unrealized gain on available-for-sale securities, net of tax | 6 | - | ||
| Total other comprehensive income | 6 | - | ||
| Comprehensive loss | -11,888 | - | ||
| Net loss per share - basic | -0.64 | -0.61 | ||
| Net loss per share - diluted | -0.64 | -0.61 | ||
| Weighted-average common shares outstanding - basic | 18,701,708 | 18,701,286 | ||
| Weighted-average common shares outstanding - diluted | 18,701,708 | 18,701,286 | ||
Kalaris Therapeutics, Inc. (KLRS)
Kalaris Therapeutics, Inc. (KLRS)